RE-269

RE-269, also known as ACT-333679, is a long-acting and highly selective prostacyclin receptor agonist. MRE-269, the active form or metabolite of Selexipag (NS-304), is much more selective for the IP receptor than are the prostacyclin analogs beraprost and iloprost, which also have high affinity for the EP(3) receptor.

Product Name: MRE-269, Selexipag Impurity C

CAS:475085-57-5

MW:419.51606

Application:research purpose

Shelf life:2 years

Other Names:ACT-333679

MF:C25H29N3O3

Grade Standard:Pharmaceutical grade

Purity:98% min

Exact Mass:419.221

Molecular Weight:419.516

PSA:75.550

LogP:4.9068

Target:Prostaglandin Receptor

Pathway:GPCR/G Protein

Solubility:DMSO : ≥ 50 mg/mL (119.18 mM)

Supply Ability

300 Gram/Grams per Month

Packaging & Delivery

Packing according to customer's requirements